8-K: Citius Pharmaceuticals' LYMPHIR Added to NCCN Clinical Practice Guidelines

Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a recommended treatment option for Cutaneous T-cell Lymphoma (CTCL).

Summary

• Citius Pharmaceuticals and Citius Oncology have announced that LYMPHIR, a recently FDA-approved immunotherapy, has been added to the NCCN Clinical Practice Guidelines in Oncology.
• LYMPHIR received a Category 2A recommendation, indicating a consensus that it is an appropriate treatment option for patients with Cutaneous T-cell Lymphoma (CTCL).
• The drug targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs, making it unique among CTCL therapies.
• The NCCN guidelines are considered the gold standard for clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement.
• LYMPHIR is indicated for use in Stage I-III relapsed or refractory CTCL after at least one prior systemic therapy.
• Clinical trials showed that 27% of patients experienced Capillary Leak Syndrome (CLS), with 8% experiencing Grade 3 CLS, and one fatal case.
• Visual impairment occurred in 9% of patients, and infusion-related reactions were reported in 69% of patients.
• Elevated ALT occurred in 70% of patients, and elevated AST occurred in 64% of patients.
• Management estimates the initial market for LYMPHIR currently exceeds $400 million and is growing.

Sentiment

Score: 7

Explanation: The document is positive due to the inclusion of LYMPHIR in the NCCN guidelines, which is a significant milestone. However, the risks associated with the drug, such as CLS and other adverse reactions, temper the overall sentiment.

Positives

• LYMPHIR's inclusion in the NCCN guidelines is expected to aid adoption and ease reimbursement.
• The drug has the potential to improve CTCL patient outcomes.
• LYMPHIR has robust intellectual property protections, including orphan drug designation and pending patents.
• The drug has demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity.
• LYMPHIR has received regulatory approval in Japan for the treatment of CTCL and PTCL.

Negatives

• LYMPHIR can cause Capillary Leak Syndrome (CLS), including life-threatening or fatal reactions.
• Visual impairment, including changes in visual acuity and color vision, can occur.
• Infusion-related reactions are common, with 69% of patients experiencing them.
• LYMPHIR can cause hepatotoxicity, with elevated ALT and AST levels reported in a high percentage of patients.
• The drug can cause fetal harm and is not recommended for pregnant or breastfeeding women.

Risks

• Capillary Leak Syndrome (CLS) is a significant risk, with a 27% incidence rate in clinical trials and one fatal case.
• Visual impairment is a potential risk, with 9% of patients experiencing it.
• Infusion-related reactions are common, requiring premedication and monitoring.
• Hepatotoxicity is a risk, with elevated liver enzymes reported in a high percentage of patients.
• The drug can cause fetal harm and is not recommended for pregnant or breastfeeding women.
• There are risks associated with commercializing LYMPHIR and other product candidates, including the need for additional funding and dependence on third-party suppliers.

Future Outlook

The company expects that the addition of LYMPHIR to the NCCN Guidelines may aid adoption and ease reimbursement, particularly for patients that qualify for Center for Medicare and Medicaid (CMS) coverage.

Management Comments

• We are grateful to the NCCN board for its recognition of LYMPHIR, paving the way for expanded access to this important treatment option, stated Leonard Mazur, CEO of Citius Pharma and Citius Oncology.
• We believe that LYMPHIR has the potential to improve CTCL patient outcomes, and expect its addition to the NCCN Guidelines may aid adoption and ease reimbursement, particularly for the anticipated patients that qualify for Center for Medicare and Medicaid (CMS) coverage, added Mazur.

Industry Context

The inclusion of LYMPHIR in the NCCN guidelines is a significant step for Citius, as these guidelines are widely used by healthcare professionals and influence reimbursement decisions. This positions LYMPHIR as a key treatment option in the competitive CTCL market.

Comparison to Industry Standards

• The NCCN guidelines are considered the gold standard for clinical decision-making in oncology, similar to the ESMO guidelines in Europe, and the inclusion of LYMPHIR is a positive sign for its acceptance.
• LYMPHIR's unique mechanism of action, targeting the IL-2 receptor, differentiates it from other CTCL therapies, such as mogamulizumab (Poteligeo) and romidepsin (Istodax), which have different targets and mechanisms.
• The reported incidence of Capillary Leak Syndrome (CLS) at 27% is a significant safety concern, and will need to be carefully managed, as other therapies such as interleukin-2 based therapies also have a risk of CLS.
• The estimated market size of $400 million is a significant opportunity, but will depend on the uptake of LYMPHIR and its reimbursement status.

Stakeholder Impact

• Shareholders will likely view the NCCN guideline inclusion positively, potentially increasing the value of the company.
• Patients with CTCL will have a new treatment option that is supported by clinical evidence and recommended by the NCCN.
• Healthcare professionals will have a clear guideline for using LYMPHIR in their treatment protocols.
• Payors will need to consider the reimbursement implications of LYMPHIR's inclusion in the NCCN guidelines.

Next Steps

• Citius is actively engaged with the FDA to outline next steps for Mino-Lok and Halo-Lido programs.
• The company will continue to monitor and manage the safety profile of LYMPHIR, including CLS and other adverse reactions.
• Citius will work to ensure that LYMPHIR is accessible to patients and that reimbursement is available.

Key Dates

Keywords

LYMPHIR, CTCL, NCCN Guidelines, Cutaneous T-cell Lymphoma, Immunotherapy, Denileukin Diftitox, Oncology, FDA Approval, Capillary Leak Syndrome, Interleukin-2 Receptor